Celldex Therapeutics, Inc. (CLDX) stock forecast and price target
Price $28.83 · data as of November 13, 2026
12-month price target
Average target$64.00
Upside / downside+122.0%
Analysts14
ConsensusStrong buy
Low $29.00Average $64.00High $100.00
Gold marker: average target · white marker: today’s price ($28.83)
Analyst ratings
Strong buy 2Buy 12Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-4.05 | −3.8% | $1M |
| Next fiscal year ends December 31, 2027 | $-4.21 | −4.0% | $7M |
| Next quarter ends December 31, 2026 | $-1.00 | +17.7% | $2M |
| Quarter after ends March 31, 2027 | $-0.97 | +17.5% | $250000 |
Consensus of the analysts covering Celldex Therapeutics, updated daily. In the last 30 days 3 estimates were raised and 1 lowered.
Frequently asked questions
What is the Celldex Therapeutics stock price target?
The average 12-month target from 14 analysts is $64.00, 122.0% above the current price of $28.83 Targets range from $29.00 to $100.00.
Is Celldex Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 12 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Celldex Therapeutics expected to earn?
Analysts expect EPS of $-4.05 for the fiscal year ending December 31, 2026 and $-4.21 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.